Trials / Recruiting
RecruitingNCT06691061
The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
Real-life Comparative Effectiveness of Vedolizumab, Ustekinumab and JAK Inhibitors in Patients with Ulcerative Colitis After Anti-TNFα Failure or Intolerance
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (estimated)
- Sponsor
- Humanitas Clinical and Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed to at least one anti-TNF-alpha therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vedolizumab | UC patients treated with vedolizumab |
| DRUG | Ustekinumab - Standard Dosage | UC patients treated with ustekinumab |
| DRUG | JAK Inhibitor | UC patients treated with JAK inhibitors |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2024-11-15
- Last updated
- 2024-11-15
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06691061. Inclusion in this directory is not an endorsement.